This antibody specifically binds to FGFR4 and is most effective (approximately 90%) in FGF19-expressing models, suggesting it as a potential drug for HCC with an activated FGF19–FGFR4 pathway. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.